Carasent Q3: Accelerating Organic Growth and Positive EBITDA-CAPEX - Redeye

Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organic growth and positive EBITDA-CAPEX – to a somewhat higher degree than expected. In addition, we are encouraged by the positive statements about the surgical functionality.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045538/carasent-q3-accelerating-organic-growth-and-positive-ebitda-capex?utm_source=finwire&utm_medium=RSS